Socioeconomic and insurance-related disparities in disease-specific survival among patients with metastatic bone disease
- PMID: 36121418
- DOI: 10.1002/jso.27097
Socioeconomic and insurance-related disparities in disease-specific survival among patients with metastatic bone disease
Abstract
Background: Approximately 5% of cancer patients in the United States presented with metastatic bone disease (MBD) at diagnosis. Current study explores the disparities in survival for patients with MBD.
Methods: Patients with the diagnosis of MBD at presentation for the five most common primary anatomical sites were extracted from Surveillance, Epidemiology, and End Results Census tract-level dataset (2010-2016). Kaplan-Meier and Cox Proportional Hazard models were used to evaluate survival, and prognostic factors for each cohort. Prognostic significance of socioeconomic status (SES) and insurance status were ascertained.
Results: The five most common anatomical-sites with MBD at presentation included "lung" (n = 59 739), "prostate" (n = 19 732), "breast" (n = 16 244), "renal and urothelium" (n = 7718) and "colon" (n= 3068). Lower SES was an independent risk factor for worse disease-specific survival (DSS) for patients with MBD originating from lung, prostate, breast and colon. Lack of insurance was an independent risk factor for worse DSS for MBD patients with primary tumors in lung and breast.
Conclusions: MBD patients from the five most common primary sites demonstrated SES and insurance-related disparities in disease-specific survival. This is the first and largest study to explore SES and insurance-related disparities among patients specifically afflicted with MBD. Our findings highlight vulnerability of patients with MBD across multiple primary sites to financial toxicity.
Keywords: disparities; insurance; metastatic bone disease; socioeconomic; survival.
© 2022 Wiley Periodicals LLC.
Similar articles
-
Sex, racial/ethnic and socioeconomic disparities in patients with metastatic bone disease.J Surg Oncol. 2022 Mar;125(4):766-774. doi: 10.1002/jso.26765. Epub 2021 Dec 10. J Surg Oncol. 2022. PMID: 34889456 Free PMC article.
-
Socioeconomic and insurance status are independent prognostic indicators of higher disease stage and worse prognosis in bladder cancer.Urol Oncol. 2019 Oct;37(10):784-790. doi: 10.1016/j.urolonc.2019.04.021. Epub 2019 May 8. Urol Oncol. 2019. PMID: 31076355
-
Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.Milbank Q. 2018 Dec;96(4):706-754. doi: 10.1111/1468-0009.12355. Milbank Q. 2018. PMID: 30537364 Free PMC article.
-
Socioeconomic factors and breast carcinoma in multicultural women.Cancer. 2000 Mar 1;88(5 Suppl):1256-64. doi: 10.1002/(sici)1097-0142(20000301)88:5+<1256::aid-cncr13>3.0.co;2-3. Cancer. 2000. PMID: 10705364 Review.
-
Socioeconomic disparities in musculoskeletal oncology.J Surg Oncol. 2023 Sep;128(3):425-429. doi: 10.1002/jso.27361. J Surg Oncol. 2023. PMID: 37537984 Review.
Cited by
-
Area Socioeconomic Status is Associated with Refusal of Recommended Surgery in Patients with Metastatic Bone and Joint Disease.Ann Surg Oncol. 2024 Aug;31(8):4882-4893. doi: 10.1245/s10434-024-15299-5. Epub 2024 Jun 11. Ann Surg Oncol. 2024. PMID: 38861205 Free PMC article.
References
REFERENCES
-
- Surveillance, Epidemiology and End Result (SEER). NCI; 2021. Accessed 03/14/21.
-
- Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304-1312.
-
- NCI. Financial burden of cancer care. 2021; https://progressreport.cancer.gov/after/economic_burden. Accessed 12/14/21, 2021.
-
- Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109(11):2334-2342.
-
- Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020;8(7):482.